Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.63 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.55 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.55 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427098 | 1.00 | ENPP2 (0.63) | ENPP2ORAI1ORAI2ORAI3TP53 | |
| SCHEMBL4973256 | 0.83 | ENPP2 (0.45) | ENPP2ORAI1ORAI2ORAI3LMNA | |
| SCHEMBL23077788 | 0.82 | ENPP2 (0.45) | ENPP2ORAI1ORAI2ORAI3TP53 | |
| SCHEMBL29470875 | 0.81 | ENPP2 (0.48) | ENPP2ORAI1ORAI2ORAI3LMNA | |
| SCHEMBL1445093 | 0.81 | ENPP2 (0.48) | ENPP2ORAI1ORAI2ORAI3LMNA | |
| SCHEMBL25745449 | 0.79 | ENPP2 (0.42) | ENPP2ORAI1ORAI2ORAI3MAPT | |
| SCHEMBL630768 | 0.79 | CA1 (0.58) | ENPP2ORAI1ORAI2ORAI3TP53 | |
| SCHEMBL2031080 | 0.79 | ENPP2 (0.42) | ENPP2ORAI1ORAI2ORAI3LMNA | |
| SCHEMBL29957207 | 0.79 | ENPP2 (0.42) | ENPP2ORAI1ORAI2ORAI3KDM4E | |
| SCHEMBL29952273 | 0.79 | ENPP2 (0.42) | ENPP2ORAI1ORAI2ORAI3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 770 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| CN-116283797-B | Synthesis method of oxaagoli sodium | 浙江车头制药股份有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-114641468-B | Process for synthesizing ELAGOLIX sodium salt and intermediate of said process | 工业化学有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-117624061-A | Production process of oxaagoli sodium | 宣城美诺华药业有限公司 | 2024-03-01 | — | — | CN | claimed |
| US-11858901-B2 | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | MOEHS IBERICA, S.L. (ES) | 2024-01-02 | — | — | US | claimed |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-12-12 | — | — | US | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| WO-2021130776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-07-01 | — | — | WO | claimed |
| WO-2021044230-A1 | PROCESS FOR THE SYNTHESIS OF THE SODIUM SALT OF 4-[[(LR)-2-[5-(2-FLUORO-3-METHOXYPHENYL)-3-[[2-FLUORO-6-(TRIFLUOROMETHYL)-PHENYL]METHYL]-3,6-DIHYDRO-4-METHYL-2,6-DIOXO-L(2H)-PYRIMIDINYL]-L- PHENYLETHYL]AMINO]-BUTANOIC ACID (ELAGOLIX SODIUM SALT) AND INTERMEDIATES OF SAID PROCESS | INDUSTRIALE CHIMICA S.R.L. (IT) | 2021-03-11 | — | — | WO | claimed |
| WO-2020240375-A1 | IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES | DR. REDDY’S LABORATORIES LIMITED (IN) | 2020-12-03 | — | — | WO | claimed |
| CN-110204498-B | Method for efficiently synthesizing oxagoril intermediate | 奥锐特药业股份有限公司 | 2020-11-27 | — | — | CN | claimed |
| CN-110204498-A | A method of it efficiently synthesizes and dislikes La Geli intermediate | 奥锐特药业股份有限公司 | 2019-09-06 | — | — | CN | claimed |
| WO-2018198086-A1 | PROCESS FOR THE PREPARATION OF ELAGOLIX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LUPIN LIMITED (IN) | 2018-11-01 | — | — | WO | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | ENPP2 854/4885ORAI1 3414/4885ORAI2 4022/4885 |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | ELP1, BPNT1, EPX | ENPP2 452/4885ORAI1 1965/4885ORAI2 1808/4885 |
| US-11858901-B2 | 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix | JAK2, EML4, AZI2 | ENPP2 530/4885ORAI1 4424/4885ORAI2 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.